রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Viglimet is indicated for:
Management of type 2 diabetes mellitus
Used when diet and exercise alone do not provide adequate glycemic control
Can be prescribed as initial therapy or added to other antidiabetic agents
Viglimet combines:
Sitagliptin: A DPP-4 inhibitor that increases incretin hormones, enhancing insulin release and suppressing glucagon secretion.
Metformin: A biguanide that reduces hepatic glucose production and improves peripheral insulin sensitivity.
The combination provides complementary mechanisms for better glucose control.
Typically 1 tablet twice daily with meals, or as directed by physician
Dose adjustments based on therapeutic response and tolerability
Take orally with meals to minimize gastrointestinal side effects. Swallow whole without crushing or chewing.
Alcohol increases risk of lactic acidosis with Metformin
May interact with cationic drugs like digoxin
Concomitant use with insulin or sulfonylureas may increase hypoglycemia risk
Severe renal impairment (eGFR <30 ml/min/1.73 m²)
Metabolic acidosis including diabetic ketoacidosis
Hypersensitivity to Sitagliptin, Metformin, or excipients
Gastrointestinal symptoms: nausea, diarrhea, abdominal discomfort
Rare: lactic acidosis, pancreatitis, allergic reactions
Sitagliptin-related: joint pain, upper respiratory symptoms
Use only if clearly needed and prescribed by doctor
Consult before use during breastfeeding
Monitor kidney function periodically
Discontinue before iodinated contrast imaging
Use cautiously in elderly and those with cardiovascular disease
Oral Antidiabetic Combination (DPP-4 inhibitor + Biguanide)
Store below 25°C
Protect from moisture and light
Keep out of reach of children